PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Gabriel N Hortobagyi Selected Research
Carcinoma (Carcinomatosis)
06/2007
Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver.
09/2006
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
06/2006
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
08/2005
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.
08/2005
Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
03/2005
Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma.
10/2004
Colitis in patients with breast carcinoma treated with taxane-based chemotherapy.
07/2004
Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma.
07/2004
Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, PA.
06/2004
Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania.
05/2004
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma.
04/2004
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
02/2004
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
02/2004
Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence.
09/2003
Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks.
09/2003
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.
07/2003
Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.
06/2003
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma.
04/2003
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
11/2002
Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study.
06/2002
Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.
05/2002
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
Articles by Research Topic
Disease
96
Breast Neoplasms (Breast Cancer)
10/2008 - 01/2002
22
Carcinoma (Carcinomatosis)
06/2007 - 05/2002
16
Neoplasms (Cancer)
06/2008 - 06/2002
6
Neoplasm Metastasis (Metastasis)
01/2008 - 08/2005
2
Residual Neoplasm
07/2007 - 10/2006
2
Lobular Carcinoma
12/2006 - 01/2005
2
Male Breast Neoplasms (Male Breast Cancer)
07/2006 - 06/2002
1
Obesity
09/2008
1
Pancreatic Neoplasms (Pancreatic Cancer)
09/2008
1
Osteonecrosis (Kienbock's Disease)
06/2008
1
Phyllodes Tumor (Cystosarcoma Phylloides)
11/2007
1
Heart Failure
09/2007
1
Inflammation
08/2007
1
Noninfiltrating Intraductal Carcinoma (DCIS)
07/2007
1
Ductal Carcinoma
12/2006
1
Vasculitis (Vasculitides)
07/2006
1
Death (Near-Death Experience)
03/2005
1
Pneumonia (Pneumonitis)
11/2004
1
Colitis
10/2004
1
Neutropenia
01/2003
1
Ovarian Neoplasms (Ovarian Cancer)
11/2002
1
Pathologic Constriction (Stenosis)
06/2002
Drug/Important Bio-Agent (IBA)
13
Paclitaxel (Taxol)
FDA Link
Generic
03/2008 - 05/2002
13
Doxorubicin (Adriamycin)
FDA Link
Generic
11/2007 - 01/2002
9
docetaxel (Taxotere)
FDA Link
06/2008 - 01/2002
7
trastuzumab (Herceptin)
FDA Link
01/2007 - 04/2002
7
Fluorouracil (Carac)
FDA Link
Generic
01/2007 - 01/2002
7
Cyclophosphamide (Cytoxan)
FDA Link
Generic
01/2007 - 01/2002
6
Biological Markers (Surrogate Marker)
IBA
12/2006 - 06/2002
5
Estrogens (Estrogen)
FDA Link
10/2008 - 07/2003
4
Epidermal Growth Factor Receptor (EGF Receptor)
IBA
10/2007 - 06/2005
4
taxane
IBA
08/2007 - 02/2002
3
capecitabine (Xeloda)
FDA Link
08/2007 - 09/2003
3
Epirubicin (Ellence)
FDA Link
Generic
01/2007 - 06/2005
2
Diphosphonates
IBA
06/2008 - 05/2008
2
erlotinib (CP 358,774)
FDA Link
08/2007 - 06/2007
2
Hormones
IBA
05/2007 - 03/2005
2
tau Proteins (tau Protein)
IBA
04/2007 - 06/2005
2
Tamoxifen
FDA Link
Generic
07/2006 - 01/2002
2
gemcitabine
FDA Link
09/2003 - 05/2002
2
vinorelbine (Navelbine)
FDA Link
Generic
05/2002 - 01/2002
2
5-ethynyluracil (eniluracil)
IBA
05/2002 - 02/2002
1
Lysine (L-Lysine)
FDA Link
09/2008
1
Histones (Histone)
IBA
09/2008
1
lapatinib (GW572016)
FDA Link
07/2008
1
Cisplatin (Platino)
FDA Link
Generic
05/2008
1
Dacarbazine (DIC)
FDA Link
Generic
11/2007
1
STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
IBA
10/2007
1
ixabepilone (BMS 247550)
FDA Link
08/2007
1
I-kappa B Kinase
IBA
08/2007
1
Cyclin-Dependent Kinase 2
IBA
08/2007
1
DNA (Deoxyribonucleic Acid)
IBA
12/2006
1
Cyclins
IBA
10/2006
1
Phosphotransferases (Kinase)
IBA
10/2006
1
temozolomide (Temodar)
FDA Link
09/2006
1
Aromatase (CYP19)
IBA
07/2006
1
Leuprolide (Lupron)
FDA Link
Generic
07/2006
1
Cytosine Deaminase
IBA
01/2006
1
Endostatins
IBA
01/2006
1
Transcription Factors (Transcription Factor)
IBA
12/2005
1
Paraffin
IBA
10/2005
1
albumin-bound paclitaxel
FDA Link
09/2005
1
tariquidar (XR9576)
IBA
08/2005
1
P-Glycoprotein
IBA
08/2005
1
RNA-Directed DNA Polymerase (Reverse Transcriptase)
IBA
05/2005
1
Carmustine (FIVB)
FDA Link
11/2004
1
Thiotepa (Triethylenethiophosphoramide)
FDA Link
Generic
11/2004
1
Taxoids
IBA
07/2004
1
Protein Kinases (Protein Kinase)
IBA
02/2004
1
Proteins (Proteins, Gene)
IBA
01/2004
1
fludarabine
IBA
11/2003
1
Melphalan (Alkeran)
FDA Link
11/2003
1
NF-kappa B (NF-kB)
IBA
11/2003
1
sulindac sulfone (exisulind)
IBA
09/2003
1
pegylated liposomal doxorubicin
IBA
09/2003
1
DX 8951 (DX 8951f)
IBA
09/2003
1
Filgrastim (Neupogen)
FDA Link
07/2003
1
RNA (Ribonucleic Acid)
IBA
06/2003
1
bexarotene (LGD1069)
FDA Link
03/2003
1
Estrogen Receptors
IBA
03/2003
1
Cyclin E
IBA
11/2002
1
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
IBA
11/2002
1
Luteinizing Hormone (Lutropin)
FDA Link
Generic
11/2002
1
annamycin
IBA
07/2002
1
anastrozole (Arimidex)
FDA Link
06/2002
1
Granulocyte Colony-Stimulating Factor (G-CSF)
IBA
01/2002
Therapy/Procedure
55
Drug Therapy (Chemotherapy)
09/2008 - 06/2002
9
Adjuvant Chemotherapy
10/2008 - 05/2002
6
Mastectomy (Mammectomy)
12/2006 - 07/2002
5
Neoadjuvant Therapy
03/2008 - 06/2005
2
Adjuvant Radiotherapy
10/2005 - 03/2005
1
Biological Therapy
05/2007
1
Hematopoietic Stem Cell Transplantation
11/2004
1
Aftercare (After-Treatment)
02/2004
1
Stem Cell Transplantation
11/2003
1
Estrogen Replacement Therapy
11/2002